Nls pharmaceutics ceo issues letter to shareholders

Zurich, switzereland / accesswire / december 22, 2022 / nls pharmaceutics ltd. (nasdaq:nlsp)(nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announces that its chief executive officer, alex zwyer, has issued the following letter to shareholders: to our shareholders and friends, just under two years ago, nls pharmaceutics sought your investment and support to advance our pipeline in rare sleep disorders and other rare and debilitating central nervous system disorders.
NLSP Ratings Summary
NLSP Quant Ranking